ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

Padeliporfin VTP therapy shows high efficacy with an 86.5% overall response rate and 73% complete response rate in low-grade UTUC. The therapy provides an organ-sparing alternative to ...

The AMPLITUDE trial explores niraparib with abiraterone acetate for metastatic castration-sensitive prostate cancer, focusing on radiographic progression-free survival. CAN-2409 combined with ...

Paul E. Dato, MD, discusses how triplet therapy involving ADT, docetaxel chemotherapy, and an androgen receptor targeting agent would be the best treatment option for this patient with high-volume, ...

Paul E. Dato, MD, discusses how the absence of genetic alterations in the second case makes the patient ineligible for PARP inhibitor therapy until castration resistance develops, with focus remaining ...

A recent study by Moyer et al (2025) provides real-world data on the efficacy and safety of nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC).

The test demonstrated comparable or superior performance in Black and Non-White men. IsoPSA demonstrated comparable or superior diagnostic performance in Black and non-White men, underscoring its ...